Derek Bagley, Author at Endocrine News

Childhood Sedentariness May Cause Premature Liver Damage in Young Adulthood

Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, according to a study presented at ENDO 2024 and published in Nature’s npj Gut and Liver. “We found that this relationship between sedentariness and liver damage is likely...

Full Circle: Q&A with New Endocrinology Editor-in-Chief, Zane Andrews, PhD

When Zane Andrews, PhD, published his very first scientific paper while working on his PhD in 2001, it was in the pages of the Endocrine Society’s Endocrinology. This month, he assumes his newest role as Endocrinology’s editor-in-chief. This month, Zane Andrews, PhD, of Monash University in Melbourne, Australia, will begin his tenure as editor-in-chief of...

In Touch
- Member News
- Society News

Meet New Endocrine Society President, John Newell-Price, MD, PhD

The Endocrine Society is pleased to welcome its president for 2024 – 2025, John Newell-Price, MD, PhD, FRCP, who took office during ENDO 2024 in Boston. Newell-Price is Professor of Endocrinology at the University of Sheffield, United Kingdom. He is also head of the Endocrinology Service at Sheffield Teaching Hospitals NHS Foundation Trust and of...

Body Positive: A Closer Look at BMI Criteria for Gender-Affirming Surgery

Body mass index (BMI) requirements for gender-affirming surgeries can sometimes present an obstacle to gender transition surgery for many transgender and gender diverse people. Sean Iwamoto, MD, and John M. Taormina, MD, two of the authors of a recent Journal of Clinical Endocrinology & Metabolism paper, discuss the need for a multidisciplinary approach for these...

Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs to Be Presented at ENDO 2024

Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...

Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Presented at ECE 2024

Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...

Good Vibrations: A New FDA-Approved Device Could Offer a Solution for Osteopenia Treatment

In a first for the treatment of osteopenia, the Osteoboost — a wearable device that delivers precise vibrations to the spine and hips — promises to offer a new form of therapy for clinicians treating postmenopausal women dealing with a loss of bone density. At the beginning of 2024, the U.S. Food and Drug...

The Joy of Endocrinology: Joy Y. Wu, MD, PhD, Breaks the Glass and Bamboo Ceilings

As Endocrine News celebrates Asian American and Pacific Islander Heritage Month, we talk to Joy Y. Wu, MD, PhD, chief of the Division of Endocrinology at Stanford University about her personal and professional journey through the field of endocrinology as well as how her career path has been shaped by her mentors, colleagues, and especially...